<DOC>
	<DOCNO>NCT00028938</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Epoetin alfa may stimulate red blood cell production prevent treat anemia patient undergo radiation therapy chemotherapy . It yet know chemotherapy combine radiation therapy effective without epoetin alfa treat non-small cell lung cancer . PURPOSE : Randomized phase III trial determine effectiveness chemotherapy combine radiation therapy without epoetin alfa treat patient stage IIIA stage IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy With Without Epoetin Alfa Treating Patients With Stage IIIA Stage IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy epoetin alfa maintain hemoglobin level patient stage IIIA IIIB non-small cell lung cancer treat chemoradiotherapy . - Compare time local systemic progression patient receive chemoradiotherapy without epoetin alfa . - Compare tumor response rate overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . - Compare number transfusion patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord Karnofsky performance status ( 90-100 % vs 60-80 % ) , weight loss ( 5 % vs 6-10 % ) , baseline hemoglobin ( woman 11.0-12.4 g/dL men 11.0-13.4 g/dL vs woman 12.5-15.0 g/dL men 13.5-15.0 g/dL ) . Patients randomize 1 2 treatment arm . - Arm I : Beginning 7-10 day start chemoradiotherapy , patient receive epoetin alfa subcutaneously weekly 8 week . Patients receive paclitaxel IV 1 hour carboplatin IV 30 minute weekly 7 week . Patients undergo radiotherapy 5 day week 7 week total 33 treatment . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive paclitaxel , carboplatin , radiotherapy arm I . Quality life assess baseline , completion chemoradiotherapy , every 3 month 1 year , every 4 month 1 year , every 6 month 3 year . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 202-232 patient ( 101-116 per treatment arm ) accrue study within 1.7-2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIA IIIB nonsmall cell lung cancer ( NSCLC ) Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin 11.015 g/dL If hemoglobin 11.011.9 g/dL follow lab value require : Iron great 60 mcg/mL Transferrin saturation great 20 % Ferritin least 100 mg/mL Iron binding capacity le 400 mcg/dL RBC folate normal B12 normal Hepatic : Bilirubin le 1.5 mg/dL AST le 2 time upper limit normal Renal : Creatinine clearance least 20 mL/min Cardiovascular : No uncontrolled hypertension Pulmonary : FEV1 least 0.8 L Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity mammalian cellderived product human albumin No concurrent prior malignancy within past 2 year except non melanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 30 day since prior transfusion No prior epoetin alfa experimental form epoetin alfa Chemotherapy : No prior chemotherapy NSCLC Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy NSCLC Surgery : At least 2 week since prior thoracotomy Other : No concurrent therapy iron , folate , B12 deficiency No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>